Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Stocks in this Quantisnow insightIndustrials · Health Care
Historical context for WAT
Across the 29 sessions after earlier WAT headlines, the stock closed higher 16 times and lower 13 times, with a median move of 1.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | WAT | SPY |
|---|---|---|---|
| Oct 13, 2026 | Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release | -0.7% | -0.0% |
| Oct 1, 2026 | Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call | -3.2% | +0.2% |
| Sep 14, 2026 | Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer | +0.4% | -0.4% |
| Sep 11, 2026 | Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference | +1.7% | +0.9% |
| Sep 9, 2026 | UBS resumed coverage on Waters with a new price target | +0.5% | -0.5% |
| Aug 27, 2026 | Waters upgraded by Piper Sandler with a new price target | +1.7% | +0.7% |
Quantisnow market dataNYSE
WAT
Waters Corporation
- Market cap
- 30-day
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Listed since
- 1995
Get push alerts for WAT
Full WAT profile on Quantisnow Follow WAT and get a push notification the moment its next story breaks.